Triple Therapy for Type 1 Diabetes: Insulin, Semaglutide, and Dapagliflozin

Type 1 Diabetes Mellitus (T1DM) is an autoimmune condition where the body's immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas, necessitating lifelong insulin replacement therapy. Despite advancements in insulin delivery, many individuals with T1DM still struggle to achieve optimal glycemic control, leading to a high risk of severe long-term complications like cardiovascular disease, nephropathy, and retinopathy. This ongoing clinical trial aims to determine if adding semaglutide and dapagliflozin to insulin therapy can significantly improve blood sugar management and overall outcomes in T1DM patients.